Citius Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTXR research report →
Price Chart
About the company
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies.
- CEO
- Leonard L. Mazur
- IPO
- 2014
- Employees
- 23
- HQ
- Cranford, NJ, US
Get TickerSpark's AI analysis on CTXR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.20M
- P/E
- -0.23
- Fwd P/E
- 2.19
- PEG
- -0.00
- P/S
- 1.86
- P/B
- 0.19
- EV/EBITDA
- -0.06
- Div Yield
- 0.00%
- Gross Margin
- 19.97%
- Op Margin
- -863.92%
- Net Margin
- -651.27%
- ROE
- -67.15%
- ROIC
- -67.62%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-214,250-2.2%
- Op Income
- $-38,525,608
- Net Income
- $-37,433,911+4.4%
- EPS
- $-3.38+43.4%
- OCF Growth
- +5.8%
- FCF Growth
- +5.8%
- 52W High
- $2.19
- 52W Low
- $0.47
- 50D MA
- $0.60
- 200D MA
- $0.70
- Beta
- 1.00
- RSI (14)
- 34
- Avg Volume
- 532.30K
No earnings-call transcripts are available for CTXR yet.
- Free Float
- 98.2%
- Shares Outstanding
- 27.45M
- Float Shares
- 26.96M
of shares held by institutions
40 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Geode Capital Management, LLC | 215.54K | ▼ 30.62K |
| Vanguard Group Inc | 199.26K | ▲ 32.87K |
| Vanguard Capital Management LLC | 197.36K | ▲ 29.63K |
| Miller Financial Services LLC | 130.00K | ▲ 116.00K |
| Citadel Advisors LLC | 124.91K | ▲ 124.91K |
| Jane Street Group, LLC | 122.84K | ▲ 100.31K |
| Vanguard Fiduciary Trust Co | 77.75K | 0 |
| Blackrock, Inc. | 69.85K | ▼ 1 |
| Northern Trust Corp | 62.74K | ▲ 18.77K |
| Xtx Topco Ltd | 59.20K | ▲ 37.90K |
| Asset Advisory Group, Inc. | 59.01K | 0 |
| Bostonpremier Wealth LLC | 28.00K | ▲ 28.00K |
Held by 6 ETFs
Biggest fund positions in CTXR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 8, 25 | Mazur Leonard L | other | 125,490 |
| Aug 8, 25 | Mazur Leonard L | other | 89,388 |
| Aug 8, 25 | Mazur Leonard L | sell | 125,490 |
| Aug 8, 25 | Mazur Leonard L | sell | 89,388 |
| Aug 8, 25 | HOLUBIAK MYRON Z | other | 31,373 |
| Aug 8, 25 | HOLUBIAK MYRON Z | other | 22,344 |
| Aug 8, 25 | HOLUBIAK MYRON Z | sell | 22,344 |
| Aug 8, 25 | HOLUBIAK MYRON Z | sell | 31,373 |
| Nov 7, 24 | Webb Carol | other | 125,000 |
| Nov 7, 24 | Smith Robert Joseph | other | 125,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTXR coverage
Recent articles, reports, and earnings notes.
No research on CTXR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTXR report →Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis
defenseworld.net · Sep 21
Brokerages Set Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) PT at $5.00
defenseworld.net · Sep 16
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
prnewswire.com · Sep 3
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com · Aug 14
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com · Aug 14
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
prnewswire.com · Aug 12
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
prnewswire.com · Aug 5
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
prnewswire.com · Jul 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.